AR096893A1 - Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro - Google Patents

Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro

Info

Publication number
AR096893A1
AR096893A1 ARP140102578A ARP140102578A AR096893A1 AR 096893 A1 AR096893 A1 AR 096893A1 AR P140102578 A ARP140102578 A AR P140102578A AR P140102578 A ARP140102578 A AR P140102578A AR 096893 A1 AR096893 A1 AR 096893A1
Authority
AR
Argentina
Prior art keywords
composition
vegf
antagonist
retinotherapy
endotelium
Prior art date
Application number
ARP140102578A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR096893A1 publication Critical patent/AR096893A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
ARP140102578A 2013-07-11 2014-07-11 Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro AR096893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11

Publications (1)

Publication Number Publication Date
AR096893A1 true AR096893A1 (es) 2016-02-03

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102578A AR096893A1 (es) 2013-07-11 2014-07-11 Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro

Country Status (14)

Country Link
US (1) US20160159893A1 (OSRAM)
EP (1) EP3019527A2 (OSRAM)
JP (1) JP2016523956A (OSRAM)
KR (1) KR20160030504A (OSRAM)
CN (1) CN105377890A (OSRAM)
AR (1) AR096893A1 (OSRAM)
AU (3) AU2014288847A1 (OSRAM)
BR (1) BR112016000282A2 (OSRAM)
CA (1) CA2917813A1 (OSRAM)
HK (1) HK1221231A1 (OSRAM)
MX (1) MX2016000385A (OSRAM)
RU (1) RU2676303C2 (OSRAM)
TW (1) TW201536317A (OSRAM)
WO (1) WO2015004626A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
WO2017117512A2 (en) 2015-12-30 2017-07-06 Marshall University Research Corporation Compositions and methods for treating retinopathy
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539234A4 (en) * 2002-09-05 2006-02-15 Medimmune Inc METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
SI1660057T1 (sl) * 2003-08-27 2012-10-30 Ophthotech Corp Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
CA2605024C (en) * 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
DK2217329T3 (en) * 2007-11-07 2018-04-23 Anthrogenesis Corp APPLICATION OF NAVLINE BLOOD IN THE TREATMENT OF COMPLIANCES IN CONNECTION WITH PREGNANCY BIRTH
EP2349339A4 (en) * 2008-10-16 2015-01-07 Kathleen Cogan Farinas EXTENDED MEDICATION DELIVERY SYSTEM
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
EP2768504A1 (en) * 2011-10-20 2014-08-27 Avienne Pharmaceuticals GmbH Compositions for controlling vascularization in ophthalmological and dermatological diseases
HUE058912T2 (hu) * 2012-08-21 2022-09-28 Opko Pharmaceuticals Llc Liposzóma készítmények

Also Published As

Publication number Publication date
HK1221231A1 (zh) 2017-05-26
KR20160030504A (ko) 2016-03-18
AU2017204326A1 (en) 2017-07-13
RU2016104398A (ru) 2017-08-16
AU2014288847A1 (en) 2016-01-28
WO2015004626A2 (en) 2015-01-15
CA2917813A1 (en) 2015-01-15
RU2676303C2 (ru) 2018-12-27
US20160159893A1 (en) 2016-06-09
CN105377890A (zh) 2016-03-02
RU2016104398A3 (OSRAM) 2018-05-31
TW201536317A (zh) 2015-10-01
WO2015004626A3 (en) 2015-05-28
BR112016000282A2 (pt) 2017-12-12
EP3019527A2 (en) 2016-05-18
AU2019206000A1 (en) 2019-08-01
JP2016523956A (ja) 2016-08-12
MX2016000385A (es) 2016-04-29

Similar Documents

Publication Publication Date Title
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
AR111208A1 (es) ANTICUERPOS ANTI-PÉPTIDO b AMILOIDE N3PGLU Y SUS USOS
CL2017001188A1 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos.
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
EA201790398A1 (ru) Способы лечения заболевания печени
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
PH12022550450A1 (en) Anti-htra1 antibodies and methods of use thereof
BR112015027477A8 (pt) bolus, seus usos, e kit
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
PL3288588T3 (pl) Ulepszone środki sieciujące włókna kolagenowe do stosowania w leczeniu ektazji rogówki
MX2018016332A (es) Quimioterapias de combinacion.
MX2017016096A (es) Agente antihipertensivo.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?

Legal Events

Date Code Title Description
FB Suspension of granting procedure